Literature DB >> 36214997

Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.

Guoyu Huang1, Guohao Cai1, Dongwei Hu2, Jinjie Li3, Qigang Xu3, Zongjing Chen3, Bo Xu4.   

Abstract

OBJECTIVE: Specificity protein 1 (SP1), a transcription factor mediated by SUMOylation modifiers, is upregulated in gastric cancer (GC) and shares negative correlation with patient prognosis. Here, we paid main attention to the role of SP1 SUMOylation in the drug resistance of GC cells and the possible long non-coding RNA (lncRNA) SNHG17/microRNA-23b-3p (miR-23b-3p)/Notch2 network engaged in this process.
METHODS: Tumor tissues and non-tumor tissues were isolated from GC patients who received treatment with capecitabine and cisplatin (DDP). Co-immunoprecipitation was utilized to detect the SUMOylation level of SP1. Using gain- and loss-of-function approaches, we assessed the impacts of SNHG17/miR-23b-3p/Notch2 on sensitivity of DDP-resistant GC cells in vitro and in vivo. A series of assays such as luciferase activity detection and RNA pull-down were conducted for mechanistic exploration.
RESULTS: SP1 expression was increased due to low SP1 SUMOylation level in the recurrent GC tissues. This increase led to upregulated SNHG17 expression and SP1 binding sites existed in the SNHG17 promoter. In addition, SNHG17 could bind to miR-23b-3p while miR-23b-3p targeted Notch2. Loss of SNHG17 reduced the resistance of DDP-resistant GC cells to DDP, which was achieved through miR-23b-3p-dependent Notch2 inhibition. Finally, SP1 silencing attenuated the resistance of GC to DDP in mice.
CONCLUSION: Low SP1 SUMOylation induces SNHG17 upregulation and blocks miR-23b-3p-induced Notch2 inhibition, contributing to the resistance of GC to DDP. This study may aid in the development of therapeutic targets overcoming the chemoresistance of GC.
© 2022. Springer Nature Switzerland AG.

Entities:  

Keywords:  Drug resistance; Gastric cancer; Notch2; SNHG17; SUMOylation; microRNA-23b-3p

Year:  2022        PMID: 36214997     DOI: 10.1007/s13402-022-00722-4

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   7.051


  41 in total

1.  A comprehensive compilation of SUMO proteomics.

Authors:  Ivo A Hendriks; Alfred C O Vertegaal
Journal:  Nat Rev Mol Cell Biol       Date:  2016-07-20       Impact factor: 94.444

Review 2.  Update on gastric cancer treatments and gene therapies.

Authors:  Alessio Biagioni; Ileana Skalamera; Sara Peri; Nicola Schiavone; Fabio Cianchi; Elisa Giommoni; Lucia Magnelli; Laura Papucci
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

Review 3.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

Review 4.  Gastric cancer.

Authors:  Eric Van Cutsem; Xavier Sagaert; Baki Topal; Karin Haustermans; Hans Prenen
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

Review 5.  Genetics of gastric cancer.

Authors:  Mairi H McLean; Emad M El-Omar
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-08-19       Impact factor: 46.802

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 7.  How to stomach an epigenetic insult: the gastric cancer epigenome.

Authors:  Nisha Padmanabhan; Toshikazu Ushijima; Patrick Tan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

Review 8.  Does surgery have a role in managing incurable gastric cancer?

Authors:  Sri G Thrumurthy; M Asif Chaudry; Ian Chau; William Allum
Journal:  Nat Rev Clin Oncol       Date:  2015-08-11       Impact factor: 66.675

Review 9.  New agents on the horizon in gastric cancer.

Authors:  F Lordick; K Shitara; Y Y Janjigian
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

10.  Uncovering global SUMOylation signaling networks in a site-specific manner.

Authors:  Ivo A Hendriks; Rochelle C J D'Souza; Bing Yang; Matty Verlaan-de Vries; Matthias Mann; Alfred C O Vertegaal
Journal:  Nat Struct Mol Biol       Date:  2014-09-14       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.